Randomized controlled trial

Randomized controlled trial
Name	Randomized controlled trial
Purpose	To evaluate interventions using random allocation and control

Randomized controlled trial is a study design that allocates participants by chance to receive one or more interventions or a comparator to assess efficacy and safety. Originating from clinical and public health research, it underpins evidence used by institutions like World Health Organization, Food and Drug Administration, National Institutes of Health, and Cochrane to guide policy and practice. Trials frequently involve collaborations among organizations such as Centers for Disease Control and Prevention, European Medicines Agency, and academic centers like Johns Hopkins University, Harvard University, and University of Oxford.

Introduction

Randomized controlled trials compare interventions by assigning subjects randomly to groups to control for confounding and allow causal inference; prominent early uses involved investigators at London School of Hygiene & Tropical Medicine and trials influencing outcomes in contexts linked to World War II, Great Depression, and public health crises like HIV/AIDS pandemic and COVID-19 pandemic. Major trials have influenced regulatory decisions by Medicines and Healthcare products Regulatory Agency and shaped guidelines from bodies such as National Institute for Health and Care Excellence and American Medical Association. Trial outcomes have altered practice in specialties represented by institutions like Mayo Clinic, Cleveland Clinic, and journals such as The Lancet and New England Journal of Medicine.

Methodology

Key methodological elements include random sequence generation, allocation concealment, blinding, and predefined endpoints; methods often reference standards promulgated by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, CONSORT, and ethics guidance from Declaration of Helsinki. Randomization techniques range from simple randomization developed in historical contexts involving statisticians at University of Cambridge and University of Edinburgh to stratified and cluster methods used in multicenter trials coordinated by networks like Global Fund and GAVI. Trial conduct relies on infrastructure including institutional review boards at places like Stanford University and data monitoring committees similar to those used in trials overseen by World Bank-funded programs.

Types and Designs

Design variants include parallel-group trials seen in cardiovascular studies at Beth Israel Deaconess Medical Center, crossover trials used in pharmacology units at University of California, San Francisco, factorial designs applied in nutrition studies affiliated with Wageningen University, adaptive platform trials exemplified by initiatives such as RECOVERY Trial infrastructure linked to University of Oxford, and cluster-randomized trials used in community interventions coordinated by UNICEF and Doctors Without Borders. Other specialized designs reference oncology consortia like European Organisation for Research and Treatment of Cancer and infectious disease platforms associated with Wellcome Trust.

Ethical and Regulatory Considerations

Ethical oversight is enforced by committees drawing on principles from Nuremberg Code and Declaration of Helsinki, with regulatory review by agencies such as Food and Drug Administration and European Medicines Agency. Informed consent processes often involve standards set by organizations like Council for International Organizations of Medical Sciences and legal frameworks influenced by rulings in jurisdictions represented by courts such as European Court of Human Rights and legislative bodies including United States Congress. Vulnerable populations in trials have protections informed by cases and guidelines from World Medical Association and advocacy by groups such as Amnesty International when trials intersect with humanitarian crises managed by International Committee of the Red Cross.

Statistical Analysis and Interpretation

Statistical inference in trials applies methods developed in part at centers like Institute for Statistical Mathematics and influenced by pioneers associated with Royal Statistical Society and researchers at Bell Labs. Analyses include intention-to-treat and per-protocol approaches featured in reports published in British Medical Journal and Journal of the American Medical Association, with interim analyses overseen by data monitoring committees modeled after panels used in major vaccine trials sponsored by Bill & Melinda Gates Foundation and Pfizer. Interpretation of effect sizes, confidence intervals, and p-values informs guideline panels at entities like World Health Organization and task forces such as the United States Preventive Services Task Force.

Limitations and Bias

Limitations include selection bias, performance bias, detection bias, and attrition bias; methodological critiques have appeared in analyses connected to debates at Institute of Medicine and commentaries in Nature and Science. External validity concerns arise when trial populations differ from clinical populations seen at centers like Kaiser Permanente or Mount Sinai Hospital, and conflicts of interest tied to industry sponsorship from companies such as GlaxoSmithKline, Roche, and Johnson & Johnson have prompted scrutiny by regulators including Securities and Exchange Commission. Reporting bias and publication bias are addressed by trial registries like ClinicalTrials.gov and initiatives championed by Open Science Framework.

History and Notable Examples

Historical milestones trace to experiments and trials linked to figures associated with institutions like University of Aberdeen and wartime studies that informed later regulation by League of Nations Health Organization precursors. Landmark trials include randomized vaccine trials influencing policy at World Health Organization, cardiovascular trials affecting practice at American College of Cardiology, and large pragmatic trials such as those run during the COVID-19 pandemic involving networks coordinated by National Institutes of Health and international consortia including Wellcome Trust and Bill & Melinda Gates Foundation. Notable completed studies and initiatives have been reported from centers like Massachusetts General Hospital, Guy's and St Thomas' NHS Foundation Trust, and consortia such as International Committee of Medical Journal Editors.

Category:Clinical research